AB0539 Comparison of RA patients in tocilizumab (TCZ) therapy who showed only DAS28(ESR) remission and both DAS28-ESR and SDAI remission

Background The TCZ treatment for RA is known that there is a discrepancy within DAS remission and SDAI remission rate cause by the weight of gravity of acute phase reactants. Especially TCZ strongly inhibits CRP which produced by the liver through the IL-6. Therefore even if we meet to the DAS remis...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.669-669
Hauptverfasser:	Yokoe, I., Kobayashi, H., Sato, H., Nishiwaki, A.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!